Clinical Trials Logo

Clinical Trial Summary

Gastroparesis is a common complication of prolonged diabetes mellitus, both with Type 1 and Type 2 forms. Treatment of diabetic gastroparesis ranges from changing dietary habits to medications and invasive procedures, all of which offer only partial and transient relief, with some options having potentially harmful effects. Acupuncture is an ancient treatment which has been found to be beneficial for many ailments, including those involving the gastrointestinal tract. We propose to evaluate whether acupuncture is an effective and safe treatment for diabetic gastroparesis using a randomized, double-blind, placebo/sham-controlled crossover trial. Because symptoms of gastroparesis do not correlate well with objective tests of gastric emptying (i.e., scintigraphy or 13C breath tests), our primary outcome value will be the Gastroparesis Cardinal Symptom Index (GCSI), a reliable and validated instrument for quantifying symptoms in these patients. As a secondary outcome we will measure gastric emptying using a C13-acetate breath test, as well as the SF-12 Short Form Health Survey. Blinding of the participants will be evaluated using a Validation of Blinding Questionnaire at the end of the treatment period.

Diabetic patients suffering from moderate gastroparesis (total GCSI score > 2.50) who fulfill the inclusion criteria (and none of the exclusion criteria) will be eligible to participate in the study. On induction, participants will fill out the GCSI questionnaire and SF-36 survey, and will undergo a C13-acetate breath test. They will then be randomly assigned to either true acupuncture treatment or placebo/sham acupuncture treatment. Each participant will undergo 8 treatments twice-weekly, for a period of 4 weeks. At the end of the eighth treatment session, each participant will again fill out a GCSI questionnaire and SF-12 form, as well as repeating the C13-acetate breath. Following a 4-week washout period, patients will be crossed over to either placebo/sham or true acupuncture treatment, again 8 twice-weekly treatments, for a period of 4 weeks. At the end of the second treatment regimen all participants will again fill out a GCSI questionnaire and SF-12 form, and undergo a C13-acetate breath test. At the end of the second treatment regimen participants will again fill out a Validation of Blinding Questionnaire.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00470795
Study type Interventional
Source Shaare Zedek Medical Center
Contact
Status Suspended
Phase Phase 3
Start date June 2009
Completion date September 2010

See also
  Status Clinical Trial Phase
Completed NCT01557296 - Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis Phase 2
Withdrawn NCT03376399 - Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms
Completed NCT02289846 - Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) Phase 2
Not yet recruiting NCT02264587 - Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Phase 4
Completed NCT03544229 - A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis Phase 2
Recruiting NCT04706832 - Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study N/A
Not yet recruiting NCT05584462 - Gastroparesis in type2 Diabetic Patient
Enrolling by invitation NCT05812339 - Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
Completed NCT02732821 - G-POEM for Treatment of Refractory Gastroparesis
Completed NCT01030341 - Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis N/A
Recruiting NCT05832151 - A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis Phase 2
Completed NCT02025725 - Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Phase 3
Completed NCT01916460 - Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients N/A
Completed NCT01469286 - Transcutaneous Electroacupuncture for Gastroparesis Phase 1
Terminated NCT00874133 - The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis N/A
Completed NCT01126034 - Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention N/A
Recruiting NCT05273788 - Thoracic Neuromodulation for Diabetic Gastroparesis N/A
Completed NCT00139893 - A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis N/A
Recruiting NCT04254549 - Rifaximin in Patients With Diabetic Gastroparesis Phase 2
Not yet recruiting NCT04661215 - Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms